157
Participants
Start Date
May 31, 2005
Primary Completion Date
March 31, 2006
Study Completion Date
March 31, 2006
Placebo
Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Bruges
Brussels
Duffel
Edegem
Leuven
Liège
Beroun
Brno
České Budějovice
Prague
Kuopio
Oys (Oulu)
Tampere
Angers
Béthune
Dijon
Grenoble
Lille
Lyon
Marseille
Montpellier
Nancy
Paris
Rennes
Strasbourg
Tain-l'Hermitage
Toulouse
Berlin
Bielefeld
Bonn
Chemnitz
Erlangen
Essen
Frankfurt
Freiburg im Breisgau
Kehl
München
Ulm
Heemstede
Heeze
Gdansk
Katowice
Lodz
Lublin
Szczecin
Warsaw
Madrid
Valencia
Vigo
Bucks
Cambridge
Cardiff
Glasgow
Hartshill
Liverpool
Newcastle
Lead Sponsor
UCB Pharma
INDUSTRY